Researchers have demonstrated that breast cancer can resurface 15 years after treatment, epigenetic editing has revealed a surprising insight into early breast cancer development and two breakthrough CDK4/6-inhibitor drugs have been approved for advanced breast cancer.
Browsing: Disease Area > Breast
A group of researchers have discovered that even 20 years after a diagnosis, women ER-positive breast cancer still face a substantial risk of cancer returning or spreading. The study could influence decisions about long-term therapy.
In this interview with the Vice President of Global Development at Amgen we take a more in-depth look at the trastuzumab data, an oncology biosimilar medicine.
The Advanced Breast Cancer Global Alliance has launched the Advanced Breast Cancer Global Charter, a bold new initiative that sets out 10 clear goals to drive global improvements in advanced breast cancer care and survival by 2025.
Researchers from the University of Georgia (GA, USA) have suggested the cause behind an increase in breast cancer genetic testing in the US in 2013.
In this opinion piece from our Editor, Jade Parker, you can discover the top 5 breast cancer advancements of 2017.
In this editorial from Future Oncology the authors explore tumor biology, host biology and patient’s quality of life in respect to circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2- metastatic breast cancer.
Researchers at the Cleveland Clinic (OH, USA) have discovered bacterial imbalances when comparing healthy and cancerous breast tissue.